{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:16:31Z","timestamp":1791832591982,"version":"4.3.4"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamaophthalmol.2020.0824","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:40:33Z","timestamp":1586446833000},"page":"610","source":"Crossref","is-referenced-by-count":30,"title":["Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity"],"prefix":"10.1001","volume":"138","author":[{"given":"Susan","family":"Vitale","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Agr\u00f3n","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarnan D. L.","family":"Keenan","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitha","family":"Domalpally","sequence":"additional","affiliation":[{"name":"Fundus Photograph Reading Center, University of Wisconsin\u2013Madison"},{"name":"Department of Ophthalmology and Visual Sciences, University of Wisconsin\u2013Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ronald P.","family":"Danis","sequence":"additional","affiliation":[{"name":"Fundus Photograph Reading Center, University of Wisconsin\u2013Madison"},{"name":"Department of Ophthalmology and Visual Sciences, University of Wisconsin\u2013Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"eoi200023r1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","article-title":"Prevalence of age-related macular degeneration in the United States.","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"eoi200023r2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ajo.2003.11.069","article-title":"The epidemiology of age-related macular degeneration.","volume":"137","author":"Klein","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi200023r3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States.","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"eoi200023r4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1172\/JCI71029","article-title":"Recent developments in the treatment of age-related macular degeneration.","volume":"124","author":"Holz","year":"2014","journal-title":"J Clin Invest"},{"issue":"14","key":"eoi200023r5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"eoi200023r6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi200023r7","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.ophtha.2006.08.015","article-title":"Laser treatment in patients with bilateral large drusen: the Complications of Age-Related Macular Degeneration Prevention Trial.","volume":"113","author":"Complications of Age-Related Macular Degeneration Prevention Trial Research Group","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi200023r8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ophtha.2018.09.015","article-title":"Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial.","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi200023r9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","article-title":"The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17 [published correction appears in Arch Ophthalmol. 2006;124(2):289-290].","volume":"123","author":"Davis","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"eoi200023r10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jamaophthalmol.2016.2383","article-title":"Evaluating the validity of the Age-Related Eye Disease Study grading scale for age-related macular degeneration: AREDS2 Report 10.","volume":"134","author":"Vitale","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi200023r11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/archophthalmol.2009.189","article-title":"Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial.","volume":"127","author":"Ying","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"eoi200023r12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00055735-200206000-00007","article-title":"Risk factors for age-related macular degeneration: an update.","volume":"13","author":"Hyman","year":"2002","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"eoi200023r13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS Report Number 12.","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200023r14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archopht.1989.01070010243030","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years.","volume":"107","author":"Klein","year":"1989","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"eoi200023r15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8 [published correction appears in Arch Ophthalmol. 2008;126(9):1251].","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"eoi200023r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"eoi200023r17","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1167\/iovs.13-11804","article-title":"Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2).","volume":"54","author":"Danis","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi200023r18","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ophtha.2012.05.027","article-title":"The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 Report Number 1).","volume":"119","author":"Chew","year":"2012","journal-title":"Ophthalmology"},{"issue":"21","key":"eoi200023r19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Cox regression analysis of multivariate failure time data: the marginal approach.","volume":"13","author":"Lin","year":"1994","journal-title":"Stat Med"},{"issue":"14","key":"eoi200023r20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"issue":"9131","key":"eoi200023r21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602].","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"eoi200023r22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/archopht.119.4.547","article-title":"How many steps of progression of diabetic retinopathy are meaningful? the Wisconsin Epidemiologic Study of Diabetic Retinopathy.","volume":"119","author":"Klein","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi200023r23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ophtha.2014.12.037","article-title":"Changes in lens opacities on the age-related eye disease study grading scale predict progression to cataract surgery and vision loss: age-related eye disease study report no. 34.","volume":"122","author":"Indaram","year":"2015","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi200023r24","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","article-title":"A simplified severity scale for age-related macular degeneration: AREDS Report No. 18.","volume":"123","author":"Ferris","year":"2005","journal-title":"Arch Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2763806\/jamaophthalmology_vitale_2020_oi_200023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T16:56:40Z","timestamp":1591894600000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2763806"}},"subtitle":["AREDS Report 41"],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0824","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}